Giant Olfactory Meningiomas: The Pterional Approach and Its Relevance for Minimizing Surgical Morbidity

Olfactory groove meningiomas may attain surprisingly large size. The subfrontal approach is currently the route preferred by most neurosurgeons for their excision. The pterional-transsylvian route represents an alternate exposure for microsurgery of frontobasal tumors. Although this approach has been already described for olfactory meningiomas, tumors of giant size were not specifically addressed in the literature. We report the application of the pterional-transsylvian approach in six patients with giant olfactory meningiomas. This series is unique because it includes only patients with tumors exceeding 6 cm in diameter with bilateral symmetrical development. A radical removal was achieved in all patients and all of them made a full recovery. To investigate the relevance of the pterional-transsylvian approach for minimizing surgical morbidity, a magnetic resonance imaging protocol was designed to characterize even subtle postoperative frontal lobe structural changes. These changes, limited to the frontal lobe ipsilateral to exposure and localized in specific anatomical domains of the prefrontal area, included cystic degenerative alterations, parenchymal gliosis, and associated persistent white matter edema. Results from the present series strengthen the usefulness of the pterional-transsylvian approach as a safe surgical route for lesions affecting the anterior skull base, even with huge bilateral symmetrical expansion, such as giant olfactory meningiomas.

[1]  K Tsuchiya,et al.  Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors. , 1996, AJNR. American journal of neuroradiology.

[2]  J. Gilsbach,et al.  Interhemispheric approach for microsurgical removal of olfactory groove meningiomas. , 1996, British journal of neurosurgery.

[3]  S. Kasoff,et al.  Resection of olfactory groove meningiomas: technical note revisited. , 1995, Surgical neurology.

[4]  R. Ojemann,et al.  Management of anterior cranial base and cavernous sinus neoplasms with conservative surgery alone or in combination with fractionated photon or stereotactic proton radiotherapy. , 1995, Clinical neurosurgery.

[5]  F. Tomasello,et al.  Peritumoral edema in meningiomas: microsurgical observations of different brain tumor interfaces related to computed tomography. , 1994, Neurosurgery.

[6]  C. Schaller,et al.  Microsurgical Removal of Olfactory Groove Meningiomas via the Pterional Approach. , 1994, Skull base surgery.

[7]  M. Sindou,et al.  Facteurs pronostiques dans la chirurgie des méningiomes intracrâniens. Rôle de la taille de la tumeur et de sa vascularisation artérielle d'origine pie-mérienne. Etude sur 150 cas. , 1993 .

[8]  M. Apuzzo Brain surgery : complication avoidance and management , 1993 .

[9]  J V Hajnal,et al.  MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. , 1992, AJNR. American journal of neuroradiology.

[10]  J. Zentner,et al.  Pterional approach for surgical treatment of olfactory groove meningiomas. , 1989, Neurosurgery.

[11]  L. Symon,et al.  Surgical management of suprasellar meningioma. Part 1: The influence of tumor size, duration of symptoms, and microsurgery on surgical outcome in 101 consecutive cases. , 1984, Journal of neurosurgery.

[12]  L. Bakay Olfactory meningiomas. The missed diagnosis. , 1984, JAMA.

[13]  D. Stuss,et al.  Neuropsychological studies of the frontal lobes. , 1984, Psychological bulletin.

[14]  Prof. Dr. med. Wolfgang Seeger Microsurgery of the Cranial Base , 1984, Springer Vienna.

[15]  S. Ganti,et al.  The importance of early diagnosis and treatment of the meningiomas of the planum sphenoidale and tuberculum sellae: a retrospective study of 105 cases. , 1979, Surgical neurology.

[16]  L. Symon Olfactory Groove and Suprasellar Meningiomas , 1977 .

[17]  L. Kempe,et al.  OPERATIVE NEUROSURGERY , 1964, Springer Berlin Heidelberg.

[18]  C. P. Rhoads,et al.  Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use. , 1951, A.M.A. archives of internal medicine.